Company intelligence / Profile preview
RegeneRx Biopharmaceuticals, Inc.
- Ownership
- Private
- Employees
- ~5
- Development stage
- Phase 3
Overview
RegeneRx’s lead candidate RGN-259 has completed multiple Phase III trials for dry eye disease and neurotrophic keratitis. While some trials did not meet all primary endpoints for DED, statistically significant improvements were observed in symptoms. For NK—a rare orphan indication—RGN-259 demonstrated efficacy in a small initial Phase III trial with ongoing pivotal studies underway in the US and Europe. Other programs are at various clinical stages targeting wound healing and cardiovascular/neurological indications.
- Therapeutic areas
- DermatologyCardiovascularOphthalmologyNeurology
- Modalities
- Peptides (notably Thymosin beta 4 and its derivatives)
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on RegeneRx Biopharmaceuticals, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RegeneRx Biopharmaceuticals, Inc..